iShares SandP Mid-Cap 400 Value ETF (IJJ)
Live price chart, market sentiment, and community perspectives for iShares SandP Mid-Cap 400 Value ETF (AMEX: IJJ).
Live price chart, market sentiment, and community perspectives for iShares SandP Mid-Cap 400 Value ETF (AMEX: IJJ).
On our desk, we are monitoring IJJ's recent push to new 52-week highs near $149.87 as a potential technical breakout, even though fundamental analysts remain cautious about its lower forward EPS growth. Watching the 50-day moving average at $145.34 closely will determine if this small-to-mid-cap rotation has the legs to sustain its current momentum.
As a risk manager, I notice that while IJJ boasts a 1.2x larger earnings yield compared to IJH, it carries heavy financial sector exposure and notable quality concerns among its underlying basket. Holdings like Ovintiv and Annaly Capital introduce leverage risks that demand a tight risk overlay.
When analyzing IJJ for tactical allocation, keep in mind its beta of 0.96 and a price-to-earnings ratio sitting comfortably around 16.13. These baseline figures confirm that while the ETF provides inexpensive exposure to the SandP 400 value tier, it lacks the aggressive growth profile needed to completely outmatch broader market benchmarks.
From a quantitative perspective, tracking Q2 2026 institutional data reveals a net inflow of over $680,000 into IJJ, with Super Investors like Cliff Asness bumping allocations up by 29.5% despite Renaissance Technologies trimming exposure slightly. This mixed institutional footprint signals a classic tactical value play rather than a core long-term compounder.
Looking at the broader market rotation narrative, the persistent strength in small- and mid-cap value shares like IJJ raises questions about whether the momentum factor's long run is finally yielding to cheaper equities. However, given its moderate rating of 70 Neutral, I am advising clients to treat it strictly as a selective holding rather than an aggressive overweight.
Explore plasma cleansing, somatic organ swaps, and BCI.